Sutro Biopharma Reports Q2 2026 Financial Results

What Happened

• On August 12, 2026, Sutro Biopharma, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release (attached to the 8-K as Exhibit 99.1). The company also disclosed an updated corporate presentation (Exhibit 99.2) under Regulation FD and posted the presentation on its Investors section at https://www.sutrobio.com/corporate-presentation/. The filing was signed by CFO Gregory Chow.

Key Details

• Filing date: August 12, 2026 (Form 8-K Items 2.02 and 7.01).
• Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
• Press release with the quarterly results is attached as Exhibit 99.1 to the 8-K.
• Updated corporate presentation attached as Exhibit 99.2 and available on the company’s investor website (Regulation FD disclosure).

Why It Matters

• The 8-K signals Sutro has publicly released its quarterly results and provided updated investor presentation materials—investors should review the press release and presentation for details on earnings, revenue, cash position, and any pipeline or guidance updates.
• The Regulation FD disclosure means the updated presentation is being broadly and publicly distributed; this is the official source for the company’s current messaging to investors.
• If you follow Sutro’s quarterly performance or pipeline progress, check the attached exhibits or the company’s investor webpage for the specific financial figures and management commentary.